Suppr超能文献

对于暴发性再生障碍性贫血初次脐带血移植后原发性移植物失败,采用基于美法仑的短期减低强度预处理进行挽救性脐带血移植。

Salvage UCBT with Short-Term Melphalan-based Reduced-Intensity Conditioning for Primary Graft Failure after Upfront UCBT for Fulminant Aplastic Anemia.

作者信息

Morita-Fujita Mari, Yabushita Tomohiro, Yoshioka Satoshi, Hiramoto Nobuhiro, Ishikawa Takayuki

机构信息

Department of Hematology, Kobe City Medical Center General Hospital, Kobe, Japan.

Department of Hematology, Graduate School of Medicine, Kyoto University, Kyoto, Japan.

出版信息

Blood Cell Ther. 2025 Mar 28;8(2):190-194. doi: 10.31547/bct-2024-023. eCollection 2025 May 25.

Abstract

Umbilical cord blood transplantation (UCBT) is a potential option for patients with very severe aplastic anemia (VSAA) when no suitable related or unrelated donor is available. However, the high incidence of graft failure following UCBT remains a major challenge. The optimal conditioning regimen for UCBT in aplastic anemia (AA), particularly for salvage UCBT after graft failure following an initial transplant, remains undetermined. We report the cases of two adolescent patients with fulminant aplastic anemia who successfully underwent salvage UCBT, conditioned by a short-term melphalan-based regimen for primary graft failure after initial UCBT. The regimen comprised fludarabine (30 mg/m) on days -4 to -2, melphalan (40 mg/m) on days -3 and -2, and total body irradiation (2 Gy) on day -1. Neutrophil engraftment occurred in both cases approximately three weeks after salvage UCBT. One patient developed grade 1 acute graft-versus-host disease (GVHD) and mild chronic GVHD, while the other experienced no GVHD. Both patients have normal complete blood counts more than two years after salvage UCBT. These cases suggest that a short-term melphalan-based regimen may be a viable conditioning option for salvage UCBT in cases of primary graft failure.

摘要

对于极重型再生障碍性贫血(VSAA)患者,在没有合适的相关或无关供体时,脐带血移植(UCBT)是一种潜在的选择。然而,UCBT后移植物失败的高发生率仍然是一个重大挑战。再生障碍性贫血(AA)患者UCBT的最佳预处理方案,特别是初次移植后移植物失败后的挽救性UCBT的最佳预处理方案,仍未确定。我们报告了两名暴发性再生障碍性贫血青少年患者成功接受挽救性UCBT的病例,他们在初次UCBT后因原发性移植物失败接受了基于马法兰的短期预处理方案。该方案包括在-4至-2天给予氟达拉滨(30mg/m²),在-3和-2天给予马法兰(40mg/m²),并在-1天给予全身照射(2Gy)。两名患者在挽救性UCBT后约三周均出现中性粒细胞植入。一名患者发生了1级急性移植物抗宿主病(GVHD)和轻度慢性GVHD,而另一名患者未发生GVHD。两名患者在挽救性UCBT两年多后全血细胞计数均正常。这些病例表明,基于马法兰的短期预处理方案可能是原发性移植物失败病例中挽救性UCBT的一种可行的预处理选择。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/62fd/12138231/2f91353206cb/2432-7026-8-2-0190-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验